VivoSeq
Other

Endoscopic Retrograde Cholangiopancreatography (ERCP)

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Endoscopic Retrograde Cholangiopancreatography (ERCP) is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures
Completed·UUniversity of California, Irvine·Phase 4·NCT00937924·304 enrolled
Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)
Completed·—·Phase 3·NCT00731198·650 enrolled
Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Completed·IIndiana University·N/A·NCT01143766·56 enrolled
Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Recruiting·UUniversiti Kebangsaan Malaysia Medical Centre·Phase 4·NCT04490031·140 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)